Company Profile
Updated: 26-OCT-09Crucell N.V.
International public company
Archimedesweg 4-6, Leiden, NL-2333 CN, Netherlands
()31 071 519 91 00, 31 071 519 98 00 fax, http://www.crucell.com
Primary SIC: Pharmaceutical Preparations, Primary NAICS: Pharmaceutical Preparation Manufacturing
Description: Manufacturing: Development, production and marketing of a range of biopharmaceutical vaccines and antibodies for the treatment of human diseases. Specialisations include hepatitis B, paediatric, respiratory and travel vaccines
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Pevion Biotech appoints Dr. Christian A. Spyr to be Head of Project Management & Clinical Development.
Vaccine Weekly; 12/9/2009; 836 words; ...Bern, Switzerland, later part of Crucell N.V.) in the fields of influenza and...merger of Berna Biotech Ltd with Crucell N.V., Dr. Spyr was appointed to the...Business, Biotechnology Company, Crucell Holland BV, Flu, Immunization...
Research and Markets Adds Report: Opportunity Analysis of H1N1 Vaccination Market.
Health & Beauty Close-Up; 11/30/2009; 814 words; ...Inc - Butantan Institute - Cantacuzino Institute Of Sera And Vaccines - Changchun Institute Of Biological Products - Crucell N.V. - CSL - Denka Seiken Co. Ltd - Green Cross Corp - Glaxosmithkline Plc - Hualan Biological Engineering Inc - Inovio...
Opportunity Analysis of H1N1 (swine flu) Vaccination Market - The Global H1N1 Influenza Vaccine Market is Estimated to be of 676 Million in 2009.
M2 Presswire; 11/23/2009; 1160 words; ...Inc - Butantan Institute - Cantacuzino Institute Of Sera And Vaccines - Changchun Institute Of Biological Products - Crucell N.V. - CSL - Denka Seiken Co. Ltd - Green Cross Corp - Glaxosmithkline Plc - Hualan Biological Engineering Inc - Inovio...
Research and Markets: Opportunity Analysis of H1N1 (swine flu) Vaccination Market - The Global H1N1 Influenza Vaccine Market is Estimated to be of 676 Million in 2009.
Business Wire; 11/23/2009; 1124 words; ...Inc * Butantan Institute * Cantacuzino Institute Of Sera And Vaccines * Changchun Institute Of Biological Products * Crucell N.V. * CSL * Denka Seiken Co. Ltd * Green Cross Corp * Glaxosmithkline Plc * Hualan Biological Engineering Inc * Inovio...
Stock Watch: TPIV, ZVTK, SDRG.
M2 Presswire; 11/4/2009; 1203 words; ...November 4, 2009: TapImmune Signs License Agreement With Crucell N.V. TapImmune Inc. (OTCBB: TPIV) announced earlier today it has signed a license agreement with Crucell N.V. About TapImmune Inc. TapImmune Inc. is a biotechnology...
Recent News Articles
- Johnson & Johnson buys 18 percent stake in Crucell.
M2 Presswire - September 28, 2009 - Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment.
PR Newswire - September 28, 2009 - Crucell N V - Therapeutic Competitors.
M2 Presswire - June 22, 2009 - Xcellerex Announces Sale of FlexFactory[TM] Bioproduction Line to Crucell for Vaccine, Monoclonal Antibody Manufacturing Facility.
Business Wire - June 17, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning